How dangerous are India’s generic drugs? Very


India relies on the weak oversight of developing countries that make up the bulk of its exports – that’s how it can continue to push substandard and often deadly medicines there. — Bloomberg

FOR a nation that seeks to claim the mantle of “pharmacy to the world,” India is scandalously short on regulatory oversight.

In the last six months, its generic cough syrups have killed dozens of children, its eye drops have caused blindness and its chemotherapy drugs have been contaminated.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
India , genericdrugs , regulation , oversight , scandals

Next In Business News

Geohan sets sights on Singapore to drive regional growth
DRB-Hicom shares up on revised US$110.62mil purchase price for Spirit MY
AirAsia X eyes second-tier cities and broader Europe-Central Asia connectivity next year
Japan's Nikkei skids in subdued Asia as bets of rate hike grow
Oil prices head for 2% weekly gain as Fed hopes boost market, Venezuela tensions loom
Ringgit opens stronger at RM4.10 vs greenback
Subdued trading on Bursa continues as traders await Fed rate decision
Trading ideas: DRB-Hicom, Al-Aqar, Haily, Pharmaniaga, Gagasan Nadi, Paragon, Orkim, BMS, VS Industry, APB, Destini, MSC, Only World, HB Global, Jetson
Indices end near flat, supported by Fed hopes
Ringgit to hold firm into next year

Others Also Read